Table 2.

Logistic regression models showing significant baseline predictors of increased augmentation index (AIx) and pulse-wave velocity (PWV). Logistic regression; all models are adjusted for age and sex and central mean arterial pressure; AIx model also adjusted for heart rate.

Variables	AIx Above 75th percentile		PWV Above 75th percentile
Variables	Univariate OR (range)	Multivariate OR (range)	Univariate OR (range)	Multivariate OR (range)
Demographic
Age	1.10 (1.04–1.17)^*	1.09 (1.02–1.16)^*	1.15 (1.07–1.24)^*	1.15 (1.06–1.26)^*
Female	9.38 (1.56–56.43)^*	8.25 (1.43–47.58)^*	0.96 (0.26–3.63)	0.88 (0.18–4.36)
Disease duration	2.02 (0.61–6.66)		2.41 (0.69–8.41)
Education level	0.38 (0.10–1.48)		0.79 (0.21–2.98)
Smoking habit	0.59 (0.18–1.96)		0.29 (0.08–1.06)
Soluble biomarker
CRP dichotomized	3.52 (1.04–11.90)^*	3.52 (1.04–11.90)^*	4.84 (1.39–16.83)^*	4.28 (1.01–18.09)^*
ESR dichotomized	2.39 (0.75–7.61)		0.94 (0.29–3.11)
IgM RF > 25 U/ml	1.38 (0.45–4.25)		0.63 (0.19–2.12)
Anti-CCP > 25 U/ml	2.39 (0.73–7.78)		0.90 (0.27–2.97)
Disease activity baseline
vdHSS	0.96 (0.90–1.03)		1.03 (0.98–1.08)
Ritchie score	1.59 (0.51–4.97)		2.48 (0.75–8.21)
Medication used at baseline
Prednisolone use	0.74 (0.19–2.90)		2.88 (0.74–11.15)
MTX use	1.97 (0.49–7.90)		1.22 (0.29–5.18)
NSAID use	0.73 (0.23–2.25)		0.75 (0.23–2.44)
Current confounders
Central mean arterial pressure	1.11 (1.04–1.17)	1.12 (1.05–1.19)	1.08 (1.02–1.15)^*	1.14 (1.05–1.23)
Statins			6.70 (1.24–36.28)	6.55 (1.12–38.44)
Nagelkerke R²		0.61		0.53

CRP dichotomized: high sensitivity C-reactive protein dichotomized at median; ESR dichotomized: erythrocyte sedimentation rate dichotomized at median; RF: rheumatoid factor; anti-CCP: anti-cyclic citrullinated peptide; vdHSS score: van der Heijde modified Sharp criteria; NSAID: nonsteroidal antiinflammatory drugs; MTX: methotrexate.
↵* p < 0.05.